Maze Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc., sold 16,142 shares of common stock on August 13, 2026 for $27.61 per share.
NASDAQ
Atul Dandekar, CSBO of Maze Therapeutics, Inc., sold 7,500 shares of common stock on July 29, 2026.
NASDAQ
Harold Bernstein, President, R&D & CMO of Maze Therapeutics, reported transactions involving common stock and stock options on July 1, 2026.
NASDAQ
Maze Therapeutics CEO Jason V. Coloma has sold a significant number of company shares through a pre-arranged trading plan.
NASDAQ
Maze Therapeutics' CSBO Atul Dandekar executed trades under a Rule 10b5-1 plan, acquiring and selling company stock.
NASDAQ
Maze Therapeutics CEO Jason V. Coloma has sold a significant number of company shares, totaling over 25,000, through a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Director Daniel Spiegelman was granted 18,000 stock options in Maze Therapeutics, Inc. as part of a standard equity incentive.
NASDAQ
Director Richard H. Scheller was granted 18,000 stock options in Maze Therapeutics, Inc. as disclosed in a recent SEC Form 4 filing.
NASDAQ
Director Jonathan E. Lim was granted 18,000 stock options in Maze Therapeutics, Inc. as part of standard equity compensation.
NASDAQ
Director Herve Hoppenot was granted 18,000 stock options in Maze Therapeutics, Inc. as part of a standard equity compensation.
NASDAQ
Director Charles J. Homcy was granted 18,000 stock options in Maze Therapeutics, Inc. as part of standard equity compensation.
NASDAQ
Director Nancy C. Andrews was granted 18,000 stock options in Maze Therapeutics, Inc. as part of a standard equity incentive.
NASDAQ
Maze Therapeutics, Inc. (MAZE) CEO Jason V. Coloma has reported the sale of company stock through a pre-arranged trading plan.
NASDAQ
Harold Bernstein, President, R&D & CMO of Maze Therapeutics, reports transactions involving common stock and stock options, executed under a Rule 10b5-1 trading plan.
NASDAQ
Maze Therapeutics' CSBO, Atul Dandekar, sold 7,500 shares of common stock for $10.42 per share under a pre-arranged 10b5-1 trading plan.
NASDAQ
Maze Therapeutics CEO Jason V. Coloma has reported the sale of company stock totaling over 32,500 shares, executed under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
CEO Jason V. Coloma sold 1,938 shares of Maze Therapeutics common stock via a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Harold Bernstein, President, R&D & CMO of Maze Therapeutics, executed a Rule 10b5-1 plan transaction involving the sale of 15,000 shares.
NASDAQ
Atul Dandekar, Chief Business Officer of Maze Therapeutics, acquired a significant number of company shares through stock options on May 4, 2026.
NASDAQ
Maze Therapeutics Director Charles J. Homcy reported a gift of 7,422 shares of common stock on May 4, 2026.
NASDAQ
Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics, liquidated 7,500 shares following an option exercise under a pre-arranged trading plan.
NASDAQ
Maze Therapeutics' Chief Scientific Business Officer, Atul Dandekar, executed a pre-planned sale of common stock following the exercise of options.
NASDAQ
Maze Therapeutics, Inc. director Neil Kumar was granted 33,417 stock options with an exercise price of $30.38, vesting monthly over three years.
NASDAQ
Maze Therapeutics' President of R&D & CMO, Harold Bernstein, exercised options and sold a significant number of common shares under a 10b5-1 plan.
NASDAQ
Harold Bernstein, President, R&D & CMO of Maze Therapeutics, exercised 30,000 stock options and subsequently sold all acquired shares under a pre-arranged trading plan.
NASDAQ
Harold Bernstein, President, R&D & CMO of Maze Therapeutics, exercised options and sold 15,000 shares of common stock under a Rule 10b5-1 plan.
NASDAQ
Amy Bachrodt, SVP of Finance at Maze Therapeutics, executed option exercises and subsequent sales of common stock totaling 5,000 shares under a pre-arranged 10b5-1 trading plan.
NASDAQ
Maze Therapeutics' CSBO Atul Dandekar reported exercising stock options and selling 7,500 shares of common stock under a pre-arranged 10b5-1 trading plan.
NASDAQ
Amy Bachrodt, SVP of Finance at Maze Therapeutics, executed a pre-planned sale of 5,000 common shares after exercising stock options on January 22, 2026.
NASDAQ
Maze Therapeutics' President of R&D & CMO, Harold Bernstein, exercised stock options and sold 25,156 shares of common stock for a significant profit.